MOMA-989 / MOMA Therapeutics - LARVOL DELTA

MOMA Therapeutics Provides Corporate Update… (Businesswire) - "MOMA-313 is currently in a Phase 1a dose escalation study designed to evaluate its potential as monotherapy and in combination with olaparib, an approved, non-selective PARP inhibitor (NCT06545942). An initial readout of olaparib combination efficacy data is anticipated in mid-2026, with development of the proprietary combination with MOMA-989 to initiate in late 2026. The company remains on track to file an IND for MOMA-341 during the first quarter of 2025....The company plans to assess the potential of MOMA-341 as a treatment for patients with cancers demonstrating microsatellite instability (MSI-H). Following successful IND clearance, MOMA anticipates an initial readout of early single agent efficacy data in mid-2026."

IND • P1 data • Breast Cancer • Microsatellite Instability • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer

MOMA Therapeutics…Announces Exclusive License Agreement for Selective PARP1 Inhibitor (Businesswire) - "MOMA Therapeutics...announced the in-licensing of a next-generation selective PARP1 (poly ADP-ribose polymerase) inhibitor, now known as MOMA-989....Under the terms of the exclusive license agreement with a U.S.-based biopharmaceutical partner, MOMA receives global rights to MOMA-989 and assumes responsibility for all further research, development and commercialization of the asset and related follow-on molecules. Selective targeting of PARP1 has demonstrated significant potential for patients with tumors displaying homologous recombination deficiency (HRD). MOMA anticipates filing an IND with the U.S. FDA by the end of 2025....Following successful IND clearance, early single agent efficacy data is anticipated in the second half of 2026."

Clinical data • IND • Licensing / partnership • Oncology • Solid Tumor